Genetic variants within ANRIL (antisense non coding RNA in the INK4 locus) are associated with risk of psoriasis.
Adolescent
Adult
Aged
Aged, 80 and over
Alleles
Case-Control Studies
Female
Gene Expression Regulation
/ immunology
Genetic Loci
/ immunology
Haplotypes
/ immunology
Humans
Iran
Male
Middle Aged
Polymorphism, Single Nucleotide
/ immunology
Psoriasis
/ genetics
RNA, Long Noncoding
/ genetics
Risk Factors
Young Adult
ANRIL
Antisense non coding RNA in the INK4 locus
Psoriasis
lncRNA
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
08
10
2019
revised:
11
11
2019
accepted:
12
11
2019
pubmed:
8
12
2019
medline:
14
7
2020
entrez:
8
12
2019
Statut:
ppublish
Résumé
Psoriasis is a systemic inflammatory disease which mostly affects skin. Evidences support the role of autoimmune responses in this disorder. The long non-coding RNA (lncRNA) antisense non coding RNA in the INK4 locus (ANRIL) has been shown to participate in modulation of immune response and in the pathogenesis of immune-related disorders. We genotyped four single nucleotide polymorphisms (SNPs) with this lncRNA (rs1333045, rs1333048, rs4977574 and rs10757278) in 286 patients with psoriasis and 300 age-/sex-matched controls to identify the role of ANRIL as a risk locus for psoriasis. The C allele of rs1333048 SNP was significantly more prevalent among cases compared with controls (OR (95% CI) = 1.56 (1.23-1.97), adjusted P value = 8.31E-4). The A allele of the rs4977574 had a protective effect against psoriasis (OR (95% CI) = 0.63 (0.49-0.81), adjusted P value = 0.001). The G allele of the rs10757278 conferred risk of psoriasis in the assessed population (OR (95% CI) = 1.9 (1.51-2.4), adjusted P value = 2.18 E-7). The C A G A haplotype (rs1333045, rs1333048, rs4977574 and rs10757278, respectively) was reported to be a protective haplotype against psoriasis (OR (95% CI) = 0.5 (0.35-0.71), adjusted P value = 0.001). The C A G G and T C G G haplotypes conferred risk of psoriasis in the assessed population (OR (95% CI) = 2.37 (1.59-3.54), adjusted P value = 2.4E-4; OR (95% CI) = 5.42 (2.88-10.22), adjusted P value = 1.1E-7, respectively). Consequently, ANRIL can be regarded as a risk locus of psoriasis in the assessed population. Future studies are needed to verify whether this contribution is exerted through modulation of immune responses.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriasis is a systemic inflammatory disease which mostly affects skin. Evidences support the role of autoimmune responses in this disorder. The long non-coding RNA (lncRNA) antisense non coding RNA in the INK4 locus (ANRIL) has been shown to participate in modulation of immune response and in the pathogenesis of immune-related disorders.
METHODS
METHODS
We genotyped four single nucleotide polymorphisms (SNPs) with this lncRNA (rs1333045, rs1333048, rs4977574 and rs10757278) in 286 patients with psoriasis and 300 age-/sex-matched controls to identify the role of ANRIL as a risk locus for psoriasis.
RESULTS
RESULTS
The C allele of rs1333048 SNP was significantly more prevalent among cases compared with controls (OR (95% CI) = 1.56 (1.23-1.97), adjusted P value = 8.31E-4). The A allele of the rs4977574 had a protective effect against psoriasis (OR (95% CI) = 0.63 (0.49-0.81), adjusted P value = 0.001). The G allele of the rs10757278 conferred risk of psoriasis in the assessed population (OR (95% CI) = 1.9 (1.51-2.4), adjusted P value = 2.18 E-7). The C A G A haplotype (rs1333045, rs1333048, rs4977574 and rs10757278, respectively) was reported to be a protective haplotype against psoriasis (OR (95% CI) = 0.5 (0.35-0.71), adjusted P value = 0.001). The C A G G and T C G G haplotypes conferred risk of psoriasis in the assessed population (OR (95% CI) = 2.37 (1.59-3.54), adjusted P value = 2.4E-4; OR (95% CI) = 5.42 (2.88-10.22), adjusted P value = 1.1E-7, respectively).
CONCLUSION
CONCLUSIONS
Consequently, ANRIL can be regarded as a risk locus of psoriasis in the assessed population. Future studies are needed to verify whether this contribution is exerted through modulation of immune responses.
Identifiants
pubmed: 31812071
pii: S1567-5769(19)32280-5
doi: 10.1016/j.intimp.2019.106053
pii:
doi:
Substances chimiques
CDKN2B antisense RNA, human
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106053Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.